"Clopidogrel May Reduce Inflammation, Thrombogenicity in HIV" - Darlene Dobkowski
According to researchers at the Icahn School of Medicine at Mount Sinai, the increased risk for CVD in patients with HIV was associated with higher thrombogenicity that interacted with immune and inflammatory activation markers, which improved with clopidogrel compared with aspirin or placebo. Published in Science Advances, results showed all study drugs were safe and well tolerated with no serious adverse events. This study shows benefits of clopidogrel in HIV patients that could reduce cardiovascular events among this vulnerable and aging population,” said Juan Badimon, PhD, professor of cardiology at the Icahn School of Medicine at Mount Sinai. “It is premature to recommend dual antiplatelet therapy for our patients with HIV at risk for cardiovascular disease,” said Judith Aberg, MD, professor of medicine and infectious diseases at the Icahn School of Medicine at Mount Sinai.
— Juan J. Badimon, PhD, Professor, Cardiology, Icahn School of Medicine at Mount Sinai, Director, Atherothrombosis Research Unit at the Cardiovascular Institute, Mount Sinai Health System
— Judith A. Aberg, MD, Professor, Medicine, Infectious Disease, Chief, Division of Infectious Diseases Clinical and Translation Research Center, Icahn School of Medicine at Mount Sinai
— Mohammad Urooj Zafar, MBBS, Clinical Researcher, Icahn School of Medicine at Mount Sinai